Evidence map›Paper›PMID 37815864›Full record

ArticleJCI insight2023

GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle.

George R Marcotte, Matthew J Miller, Hawley E Kunz, Zachary C Ryan, Matthew D Strub, Patrick M Vanderboom, Carrie J Heppelmann, Sarah Chau, Zachary D Von Ruff, Sean P Kilroe and 12 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Growth Arrest and DNA Damage Protein 45A Promotes PPRV Replication via the Downregulation of TBK1 Expression to Inhibit IFN-β Signaling Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

George R MarcotteDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Matthew J MillerDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Hawley E KunzDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Zachary C RyanDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Matthew D StrubDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Patrick M VanderboomDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Carrie J HeppelmannDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Sarah ChauDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Zachary D Von RuffUniversity of Texas Medical Branch, Galveston, Texas, USA.
Sean P KilroeUniversity of Texas Medical Branch, Galveston, Texas, USA.
Andrew T McKeenDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jason M DierdorffUniversity of Iowa, Iowa City, Iowa, USA.
Jennifer I SternDepartment of Neurology and.
Karl A NathDivision of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Chad E GrueterUniversity of Iowa, Iowa City, Iowa, USA.
Vitor A LiraUniversity of Iowa, Iowa City, Iowa, USA.
Andrew R JudgeUniversity of Florida, Gainesville, Florida, USA.
Blake B RasmussenUniversity of Texas Medical Branch, Galveston, Texas, USA.
K Sreekumaran NairDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Ian R LanzaDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Scott M EbertDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Christopher M AdamsDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USUniversity of Iowa · USThe University of Texas Medical Branch at Galveston · USMayo Clinic in Florida · USThe University of Texas Health Science Center at San Antonio · USUniversity of Florida · US

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
TRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JAMES FLOYD NELSON · 1995 to 2026
$30.6M
Enhancing Adaptations to ExerciseR01AG054454 · NIA · MAYO CLINIC ROCHESTER · PI LANZA, IAN R · 2017 to 2022
$3.3M
Exercise Response in Humans with ObesityR01DK133194 · NIDDK · MAYO CLINIC ROCHESTER · PI IAN R LANZA · 2023 to 2026
$2.8M
Novel Signaling Pathways Underlying Skeletal Muscle AtrophyR01AG060637 · NIA · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2018 to 2022
$2.6M
Molecular pathogenesis of skeletal muscle atrophyR01AR071762 · NIAMS · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2017 to 2021
$2.4M
Heme-mediated Mitochondrial Injury, Senescence, Acute Kidney Injury and Chronic Kidney DiseaseR01DK133401 · NIDDK · MAYO CLINIC ROCHESTER · PI KARL A. NATH · 2023 to 2026
$2.4M
Sex-specific determinants of early-phase recovery from skeletal muscle disuse.R01AG064386 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RASMUSSEN, BLAKE B · 2019 to 2022
$2.0M
The Murine Dialysis Fistula Model Exhibits a Senescence Phenotype: Pathobiologic Mechanisms and Therapeutic PotentialR01DK119167 · NIDDK · MAYO CLINIC ROCHESTER · PI NATH, KARL A. · 2019 to 2022
$1.7M
Development of Novel Small Molecule Therapies for Skeletal Muscle AtrophyR44AG047684 · NIA · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2018 to 2019
$1.5M
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle AtrophyR44AR069400 · NIAMS · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2020 to 2021
$1.5M
Advancing Drug Development in AL Amyloidosis: Capitalizing Natural History and Assessing EndpointsR13AG071150 · NIA · AMYLOIDOSIS RESEARCH CONSORTIUM, INC. · PI LOUSADA, ISABELLE R. · 2021 to 2021
$24k
BLRD VA I01 BX000976NCATS NIH HHS UL1 TR001439NIAMS NIH HHS R01 AR071762NIAMS NIH HHS R44 AR069400NIA NIH HHS P30 AG013319NIA NIH HHS R01 AG054454NIA NIH HHS R01 AG060637NIA NIH HHS R01 AG064386NIA NIH HHS R13 AG071150NIA NIH HHS R44 AG047684NIDDK NIH HHS R01 DK119167NIDDK NIH HHS R01 DK133194NIDDK NIH HHS R01 DK133401RRD VA I01 RX001477
6 · The paper itself

Abstract

Aging and many illnesses and injuries impair skeletal muscle mass and function, but the molecular mechanisms are not well understood. To better understand the mechanisms, we generated and studied transgenic mice with skeletal muscle-specific expression of growth arrest and DNA damage inducible α (GADD45A), a signaling protein whose expression in skeletal muscle rises during aging and a wide range of illnesses and injuries. We found that GADD45A induced several cellular changes that are characteristic of skeletal muscle atrophy, including a reduction in skeletal muscle mitochondria and oxidative capacity, selective atrophy of glycolytic muscle fibers, and paradoxical expression of oxidative myosin heavy chains despite mitochondrial loss. These cellular changes were at least partly mediated by MAP kinase kinase kinase 4, a protein kinase that is directly activated by GADD45A. By inducing these changes, GADD45A decreased the mass of muscles that are enriched in glycolytic fibers, and it impaired strength, specific force, and endurance exercise capacity. Furthermore, as predicted by data from mouse models, we found that GADD45A expression in skeletal muscle was associated with muscle weakness in humans. Collectively, these findings identify GADD45A as a mediator of mitochondrial loss, atrophy, and weakness in mouse skeletal muscle and a potential target for muscle weakness in humans.

Indexed as

Mitochondria, MuscleMuscle, SkeletalMuscular AtrophyAgingAnimalsCell Cycle ProteinsGADD45 ProteinsHumansMiceMuscle WeaknessCell Cycle ProteinsGADD45A protein, humanGADD45 ProteinsMetabolismMitochondriaMuscle BiologySkeletal muscle

Identifiers

PMID37815864
PMCPMC10721312
OpenAlexW4387494704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.